Sri Ramachandra Medical College, Chennai Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2007
NCT01187966
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Sri RamaChandra Medical Centre, Chennai, India | Sri Ramchandra Medical College

Active Ingredients

Drugs in Phase 3 Trials (1)

safinamide (xadago) (1 trial)

Drugs in Phase 2 Trials (3)

allogeneic adipose derived mesenchymal stem cell (1 trial)

gemcitabine (gemzar) (1 trial)

riviciclib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ischemia (Phase 2)

Pancreatic Neoplasms (Phase 2)

Parkinson Disease (Phase 3)

Thromboangiitis Obliterans (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4